COVID-19 company Meenta on Tuesday announced a partnership with Mirimus to provide the K-12 schools across the US with easy access to affordable clinical testing using a HIPAA-compliant, secure API integration and dashboards that turns data into actionable insights.

Mirimus has developed a COVID-19 testing platform (SalivaClear) which enables saliva-based sampling, pooled testing and individual diagnostics with just one sample from each individual. This K-12 COVID-19 testing programme is available immediately on the Meenta Marketplace, a testing marketplace that provides schools access to millions of tests from different clinical labs and diagnostic companies.

Using Mirimus' SalivaClear technology, each tube has a unique barcode that is scanned before saliva samples are collected on site and sent directly to the lab, where samples are pooled in batches of 24 samples and tested. These results are sent back to the school within 24 hours of the lab. Positive pools are re-tested in sub-pools of two samples and then individually tested if they test positive again.

The partners added that SalivaClear enables high-quality, simple, and cost-efficient detection of SARS-CoV2 to quickly isolate COVID-19 hotspots before they can become outbreaks. This approach is a highly accurate, RT-PCR-based testing strategy based on leading research from Yale University and is operating under an Emergency Use Authorization from the US FDA.